FORM 10-QSB
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

(Mark One)

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE
ACT OF 1934

                  For the quarterly period ended March 31, 2006

                                       OR

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES
EXCHANGE ACT OF 1934

                            Commission File No. 09081

                                   CYBRDI INC.
             ------------------------------------------------------
             (Exact name of registrant as specified in its charter)

         CALIFORNIA                                              95-2461404
-------------------------------                              -------------------
(State or other jurisdiction of                               (I.R.S. Employer
 incorporation or organization)                              Identification No.)

   401 Rosemont Ave. Frederick, MD                                   21701
---------------------------------------                           ----------
(Address of principal executive office)                           (Zip Code)

Registrant's telephone number, including area code:             (301) 644-3901
                                                                --------------

                                       N/A
               ---------------------------------------------------
               Former name, former address and former fiscal year,
                         (if changed since last report)

Indicate by a check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes [ ] No [x]

Indicate by a check mark whether the registrant is an accelerated filer (as
defined in Rule 12b-2 of the Exchange Act). Yes [ ]  No [x]

Indicate by a check mark whether the registrant is a shell Company (as defined
by Rule 12b-2 of the Act).

Yes [ ] No [X]

                      APPLICABLE ONLY TO CORPORATE ISSUERS:

Indicate the number of shares outstanding of each of the issuer's classes of
Common Stock as of the latest practicable date:

50,456,569shares of Common Stock, without par value, as of October 10, 2006

<PAGE>
                                      INDEX

                         PART I. - FINANCIAL INFORMATION

Item 1. Financial Statements

Condensed Consolidated Balance Sheets
as at March 31, 2006 (unaudited) and December 31, 2005

Condensed Consolidated Statements of Operations
(unaudited) for three months ended March 31, 2006 and March 31, 2005

Condensed Consolidated Statements of Cash Flow
(unaudited) for three months ended March 31, 2006 and March 31, 2005

Notes to Condensed Consolidated Financial Statements

Item 2. Management's Discussion and Analysis of Financial Condition and
        Results of Operation

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Item 4. Controls and Procedures

                          PART II. - OTHER INFORMATION

Item 1. Legal Proceedings

Item 2. Unregistered Sales of Equity Securities

Item 3. Defaults upon senior securities

Item 4. Submission of matters to a vote of security holders

Item 5. Exhibits and reports on Form 8-K

                                       2
<PAGE>
                           FORWARD LOOKING STATEMENTS

This Quarterly Report on Form 10-QSB for the quarterly period ended March 31,
2006 contains "forward-looking statements". Generally, the words "believes",
"anticipates," "may," "will," "should," "expect," "intend," "estimate,"
"continue," and similar expressions or the negative thereof or comparable
terminology are intended to identify forward-looking statements which include,
but are not limited to, statements concerning the Company's expectations
regarding its working capital requirements, financing requirements, business
prospects, and other statements of expectations, beliefs, future plans and
strategies, anticipated events or trends, and similar expressions concerning
matters that are not historical facts. Such statements are subject to certain
risks and uncertainties, including the matters set forth in this Quarterly
Report or other reports or documents the Company files with the Securities and
Exchange Commission from time to time, which could cause actual results or
outcomes to differ materially from those projected. Undue reliance should not be
placed on these forward-looking statements which speak only as of the date
hereof. The Company undertakes no obligation to update these forward-looking
statements. In addition, the forward-looking statements in this Quarterly Report
on Form 10-QSB involve known and unknown risks, uncertainties and other factors
that could cause the actual results, performance or achievements of the Company
to differ materially from those expressed in or implied by the forward-looking
statements contained herein.

ITEM 1A.
                                  RISK FACTORS

         There have been no material changes in our risk factors from those
disclosed in our 2005 Annual Report on Form 10-K.

                                       3
<PAGE>

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

CYBRDI, INC. AND SUBSIDIARY
CONSOLIDATED BALANCE SHEETS AS OF MARCH 31, 2006 AND DECEMBER 31, 2005
<TABLE>
<CAPTION>
                                                                MAR 31, 2006   DEC 31, 2005
                                                                ------------   ------------
                              ASSETS                             UNAUDITED       AUDITED
<S>                                                              <C>            <C>
CURRENT ASSETS
Cash and cash equivalents                                        $  471,700     $4,206,695
Accounts receivable                                                 332,253        360,503
Inventories                                                         309,595        263,634
Loan to unaffiliated company                                      3,654,870             --
Other receivables and prepaid expenses                              162,234         96,626
                                                                 ----------     ----------
TOTAL CURRENT ASSETS                                              4,930,652      4,927,458
PROPERTY, PLANT AND EQUIPMENT, NET                                  543,798        553,382
INTANGIBLE ASSETS (NET)                                             565,515        581,593
DEFERRED TAX ASSETS                                                  41,474         41,199
                                                                 ----------     ----------

TOTAL ASSETS                                                      6,081,439      6,103,632
                                                                 ==========     ==========

               LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES
Accounts payable and accrued expenses                                55,688         34,118
Other payables                                                       47,880         51,193
Amount due to stockholders                                          629,562        645,021
                                                                 ----------     ----------
TOTAL CURRENT LIABILITITES                                          733,130        730,332

MINORITY INTERESTS                                                1,146,591      1,149,158
                                                                 ----------     ----------

TOTAL LIABILITIES                                                 1,879,721      1,879,490
                                                                 ----------     ----------

COMMITMENTS AND CONTINGENCIES

STOCKHOLDERS' EQUITY
Preferred Stock, $1.00 per value, 500,000 shares authorized,
zero shares issued and outstanding                                       --             --
Common Stock, no par value, 150,000,000 shares authorized,
50,456,569 shares issued and outstanding as of
March 31, 2006 and December 31, 2005                                     --             --
Additional paid-in capital                                        3,601,932      3,601,932
Reserve funds                                                       336,885        336,885
Retained earnings                                                   127,648        174,416
Accumulated other comprehensive income                              135,253        110,909
                                                                 ----------     ----------
TOTAL STOCKHOLDERS' EQUITY                                        4,201,718      4,224,142

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY                       $6,081,439     $6,103,632
                                                                 ==========     ==========
</TABLE>

The accompanying notes are an integral part of these consolidated financial
statements.

                                       4
<PAGE>

CYBRDI, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
FOR THREE MONTHS ENDED MARCH 31, 2006 AND 2005
<TABLE>
<CAPTION>
                                                    THREE MONTHS ENDED     THREE MONTHS ENDED
                                                      MARCH 31, 2006         MARCH 31, 2005
                                                    ------------------     ------------------
                                                        UNAUDITED               UNAUDITED
<S>                                                    <C>                    <C>
REVENUE
      Products                                         $     83,218           $    328,063
      Service rendered                                       15,121                 30,266
                                                       ------------           ------------
           TOTAL REVENUE                                     98,339                358,329
                                                       ------------           ------------
COST OF SALES
      Products                                               43,522                 49,143
      Service rendered                                           90                  3,476
                                                       ------------           ------------
           TOTAL COST OF SALES                               43,612                 52,619
                                                       ------------           ------------
GROSS PROFIT                                                 54,727                305,710
                                                       ------------           ------------

OPERATING EXPENSES:
      Selling and distribution expenses                      28,624                 22,531
      General and administrative expenses                   139,406                161,717
                                                       ------------           ------------
TOTAL OPERATING EXPENSES                                    168,030                184,248
                                                       ------------           ------------

(LOSS) INCOME FROM OPERATIONS                              (113,303)               121,462
                                                       ------------           ------------
OTHER INCOME/(EXPENSES)
      Interest income                                        61,441                  2,058
      Other (expenses)/income, net                            2,527                 (3,049)
                                                       ------------           ------------
TOTAL OTHER INCOME (EXPENSES)                                63,968                   (991)
                                                       ------------           ------------

(LOSS) INCOME BEFORE INCOME TAXES                           (49,335)               120,471
Income Taxes (Expenses)/Benefit                                  --                  8,774
                                                       ------------           ------------
(Loss) Income before Minority Interest                      (49,335)               111,697
Minority (Loss) Interest                                     (2,567)                21,644
                                                       ------------           ------------

NET (LOSS) INCOME                                      $    (46,768)          $     90,053

Other Comprehensive Income (Loss):
Foreign Currency Translation Gain (Loss)                     24,344                    (30)
                                                       ------------           ------------

COMPREHENSIVE (LOSS) INCOME                            $    (22,424)          $     90,023
                                                       ============           ============


Weighted average number of shares outstanding            50,456,569             29,745,610
                                                       ============           ============

Earnings per share, basic and diluted                  $      (0.00)          $       0.00
                                                       ============           ============
</TABLE>

The accompanying notes are an integral part of these consolidated financial
statements.

                                       5
<PAGE>

CYBRDI INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
FOR THE THREE MONTHS ENDED MARCH 31, 2006 AND 2005
<TABLE>
<CAPTION>
                                                               THREE MONTHS ENDED     THREE MONTHS ENDED
                                                                 MARCH 31, 2006         MARCH 31, 2005
                                                               ------------------     ------------------
                                                                    UNAUDITED             UNAUDITED
<S>                                                                <C>                   <C>
CASH FLOWS FROM OPERATING ACTIVITIES
      NET INCOME (LOSS)                                            $   (46,768)          $    90,053
      Adjustments to reconcile net income to net cash
        provided by operating activities:
      Depreciation and amortization                                     34,600                50,963
      Minority interest's share of net income (loss)                    (2,567)               21,644
CHANGES IN OPERATING ASSETS AND LIABILITIES:
      Accounts receivable, net                                          30,453               (47,766)
      Inventories                                                      (43,909)               10,457
      Other receivable and prepaid expenses                            (64,532)             (102,608)
      Accounts payable and accrued expenses                             21,201                75,049
      Other payables and liabilities                                    (3,630)              (10,291)
      Income tax payable                                                    --                 8,774
      Customer Deposit                                                      --                 5,061
                                                                   -----------           -----------
      Net cash (used in) provided by operating activities              (75,152)              101,336
                                                                   -----------           -----------

CASH FLOWS FROM INVESTING ACTIVITIES
      Purchase of property, plant and equipment                         (1,584)                   --
                                                                   -----------           -----------
      Net cash (used in) investing activities                           (1,584)                   --
                                                                   -----------           -----------

CASH FLOWS FROM FINANCING ACTIVITIES
      Proceeds advanced from shareholders                                   --                11,256
      Repayment of advanced to shareholder                             (15,459)                   --
      Loan to unaffiliated company                                  (3,654,870)                   --
      Payment of dividend                                                   --              (138,507)
      Payment for merger expenses                                           --              (200,168)
                                                                   -----------           -----------
      Net cash (used in) financing activities                       (3,670,329)             (327,419)
                                                                   -----------           -----------

NET (DECREASE) INCREASE IN CASH AND
      Net decrease in cash and cash equivalents                     (3,747,065)             (226,083)
      Effect of exchange rate changes on cash                           12,070                   (26)
      Cash and cash equivalents, at beginning of period              4,206,695             3,899,706
                                                                   -----------           -----------

CASH AND CASH EQUIVALENTS, AT END OF PERIOD                        $   471,700           $ 3,673,597
                                                                   ===========           ===========
</TABLE>

The accompanying notes are an integral part of these consolidated financial
statements.

                                       6
<PAGE>

CYBRDI, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE MONTHS ENDED MARCH 31,2006(UNAUDITED)
(DOLLAR IN THOUSAND, EXCEPT NOTED OTHERWISE)

NOTE A - BASIS OF PRESENTATION

Interim financial statements:

The accompanying financial statements and footnotes have been condensed and
therefore do not contain all disclosures required by generally accepted
accounting principles. The interim financial statements are unaudited; however,
in the opinion of Cybrdi Inc. (the "Company"), the interim financial statements
include all adjustments, consisting only of normal recurring adjustments,
necessary for a fair statement of the results for the interim periods. Results
for interim periods are not necessarily indicative of those to be expected for
the full year. It is suggested that these condensed consolidated financial
statements be read in conjunction with the December 31, 2005 audited
consolidated financial statements and the accompanying notes thereto.

Description of business and revenue recognition:

On April 2, 2005 the Company filed amendments to its articles of incorporation
to change its name from Certron Corporation to Cybrdi, Inc. The amendment was
approved by the required vote of shareholders in accordance with Section 902 and
Section 903 of the California Corporations Code.

Until its acquisition of Cybrdi, Inc. on February 10, 2005, the Company's
business consisted primarily of the distribution of magnetic media products.
With the completion of the merger, all the magnetic media distribution business
activities have ceased and Certron's sole business is conducted through Cybrdi.
Cybrdi's focus is the field of biogenetics commercialization, specializing in
the rapid introduction of tissue microarray products and services in both the
international and Chinese markets.

Most of the Company's activities are conducted through its 80% equity ownership
in China Shaanxi Shaoying Bio-technology Co., Ltd. ("Chaoying Biotech") a
sino-foreign equity joint venture established in July 2000 in the People's
Republic of China. The Company, with its principal operations located in China,
aims to take advantage of China's abundant scientific talent, low wage rates,
less stringent biogenetic regulation, and the huge genetic population as it
introduces its growing list of tissue microarray products.

Revenue represents the invoiced value of goods sold recognized upon the delivery
of goods to customers and service income is recognized when services are
provided. Deferred revenue represents the undelivered portion of invoiced value
of goods sold to customers. Sales transactions not meeting all the conditions of
the full accrual method are accounted for using the deposit method of
accounting. Under the deposit method, all costs are capitalized as incurred, and
payments received from the buyer are recorded as customer deposits.

Reverse merger:

On February 10, 2005, (the "Closing Date") the Company closed on an Agreement
and Plan of Merger (the "Agreement") among Certron Corporation ("Certron"), a
California corporation, Certron Acquisition Corp., a Maryland corporation and a
wholly-owned subsidiary of Certron ("Acquisition Sub"), and Cybrdi, Inc., a
Maryland corporation ("Cybrdi - Maryland") relating to the acquisition by
Certron of all of the issued and outstanding capital stock of Cybrdi - Maryland
in exchange for shares of common stock of Certron that will aggregate
approximately 93.8% of the issued and outstanding common stock of Certron.
Pursuant to the terms of the Agreement, at the Closing Date (a) Acquisition Sub
has been merged with and into Cybrdi - Maryland, with Cybrdi - Maryland being
the surviving corporation, (b) the common stock of Cybrdi-Maryland has been
cancelled and converted into the right to receive shares of the common stock of
Certron at an exchange ratio of 1.566641609. This resulted in the issuance of
47,328,263 shares of the Certron's common stock , and (c) each share of the
common stock of Acquisition Sub has been converted in to and become one share of
the common stock of Cybrdi-Maryland. The share exchange has been accounted for
as a reverse merger under the purchase method of accounting. Accordingly, Cybrdi
Inc. will be treated as the continuing entity for accounting purposes and the
historical financial statements presented will be those of Cybrdi, Inc.

In connection with the Agreement, on February 10, 2005, the Company amended its
articles of incorporation to authorize the issuance of 150 million shares of
common stock no par value and 500,000 shares of preferred stock, $1.00 par value
per share, none of which are issued or outstanding.

Concurrent with the filing of the Articles of Merger, all of the Company's then
existing officers and directors tendered their resignation and Yanbiao Bai was
appointed as our Chairman of the Board of Directors. Mr. Bai then nominated the


                                       7
<PAGE>

following individuals to serve on the Board of Directors: Lei Liu, James Pan,
Xue Bu, Lieping Chen and MinMin Qin. The new Directors subsequently elected Dr.
Lei Liu as Chief Executive Officer, Mr. Yanbiao Bai as President, and Mrs. Xue
Bu as Secretary and Treasurer. Lieping Chen and James Pan have since tendered
their resignations as directors of the Company

On March 31, 2005 the Company's Board of Directors changed its fiscal year end
from October 31 to December 31. Certron's fiscal year end was changed to
correspond with the fiscal year end of Cybrdi - Maryland.

Principles of consolidation:

The condensed consolidated financial statements include the accounts of Cybrdi,
Inc. and its wholly-owned subsidiaries and joint ventures.

All significant intercompany balances and transactions have been eliminated.

Recent Accounting Pronouncements:

In May 2005, the FASB issued Statement No. 154, "Accounting Changes and Error
Corrections" ("FAS 154"). FAS 154 generally require that accounting changes and
errors be applied retrospectively. FAS 154 is effective for accounting changes
and corrections of errors made in fiscal years beginning after December 15,
2005. The Company does not expect FAS 154 to have a material impact on its
financial statements.

In March 2005, the FASB issued Statement of Financial Accounting Standards
Interpretation Number 47, "Accounting for Conditional Asset Retirement
Obligations" ("FIN 47"). FIN 47 provides clarification regarding the meaning of
the term "conditional asset retirement obligation" as used in FASB Statement No.
143, "Accounting for Asset Retirement Obligations." FIN 47 is effective for
fiscal years beginning after December 15, 2005. The Company is currently
evaluating the impact of FIN 47 on its financial statements.

On December 16, 2004, the Financial Accounting Standards Board ("FASB")
published Statement of Financial Accounting Standards No. 123 (Revised 2004),
Share-Based Payment ("SFAS 123R"). SFAS 123R requires that compensation cost
related to share-based payment transactions be recognized in the financial
statements. Share-based payment transactions within the scope of SFAS 123R
include stock options, restricted stock plans, performance-based awards, stock
appreciation rights, and employee share purchase plans. This standard will be
effective for awards granted, modified or settled in fiscal years beginning
after June 15, 2005. Accordingly, the Company will implement the revised
standard in the first quarter of fiscal year 2006. Management is assessing the
implications of this revised standard, which may materially impact the Company's
results of operations in fiscal year 2006 and thereafter.

NOTE B - ASSETS

The March 31, 2006 balance sheet included total current assets of $4,930,652 and
non-current assets of $1,150,787. Of these amounts, approximately $471,700 in
cash and $332,253 in accounts receivable are planned for funding current
operations and for future business expansion.

Other current assets also included inventories, loan to unaffiliated company,
and other receivable and prepaid expenses. Inventories are mainly finished goods
and very few raw materials. Inventories are stated at the lower of cost or
market. Cost of raw materials is determined on the basis of first in first out
method ("FIFO"). Finished goods are determined on the weighted average basis and
are comprised of direct materials, direct labor and an appropriate proportion of
overhead. The other primary asset included in-current assets is loan to
unaffiliated company. Loan to unaffiliated company consists of loans to QuanYe
Security Co., Ltd ("QuanYe"), an unrelated People's Republic of China ("PRC")
registered company located in Xian PRC. QuanYe is engaged in the pawnshop
business and their primary business is offering alternative financing to small
local companies. According to the loan agreement, QuanYe has received loans from
Chaoying Biotech of a total amount of RBM29.3Million (equivalent to
$3,654,870) and the details are listed as follows:

<TABLE>
<CAPTION>
-------------------- --------------------------------- --------------- ------------------- -----------------------
 CONTRACT EXECUTED                LOAN AMOUNT             INTEREST            TERM               REPAYMENT
       DATE
-------------------- ------------------ -------------- --------------- ------------------- -----------------------
<S>                     <C>                <C>               <C>             <C>                 <C>
     1/9/2006           RMB 15,000,000     $1,871,094        8%              1 year              11/16/2006
-------------------- ------------------ -------------- --------------- ------------------- -----------------------
     1/10/2006           RMB 8,300,000     $1,035,338        8%              1 year              11/25/2006
-------------------- ------------------ -------------- --------------- ------------------- -----------------------
     1/19/2006           RMB 6,000,000      $ 748,438        5%             3 months                 **
-------------------- ------------------ -------------- --------------- ------------------- -----------------------
</TABLE>
----------
** RMB1 million (equivalent to $124,740) and RMB2 million (equivalent to
   $249,479) was repaid on April 28, 2006 and June 19, 2006 respectively. Loan
   of RMB 3 million (equivalent to $374,219) was extended to September 30, 2006
   with an annual interest rate of 5%. Management believes and views QuanYe as
   an alternative financial institution and it is an optimal way to use its cash
   on hand. The regular market interest rate in the PRC is 0.72% per annum.
   Cybrdi expects to obtain higher interest income for its unused fund through
   these types of loan arrangements. However, these advances are unsecured and
   have a default risk higher than a bank deposit.

                                       8
<PAGE>

Included in-non-current assets are property, plant and equipment, intangible
assets, and deferred tax assets. Property, plant and equipment mainly consist of
building, motor vehicles, leasehold improvement, software-website, and machinery
used for product manufacturing located in the People's Republic of China
("PRC"), and office equipments located in PRC and United States. Depreciation
on property, plant and equipment is computed using the straight-line method
over the estimated useful life of the assets. The majority of the assets have
estimated useful lives of 10 years. Building and office equipments have
estimated useful lives of 20 and 5 years, respectively. Intangible assets
include a patent. Effective January 1, 2002, with the adoption of SFAS No. 142,
intangible assets with a definite life are amortized on a straight-line basis.
The patent is being amortized over its estimated life of 10 years.

NOTE C - LIABILITIES

The March 31, 2006 balance sheet included total liabilities of $1,879,721 of
which $1,146,591 represents the 20% minority interest in Chaoying Biotech.
Included in the total liabilities $629,562 was due to stockholders who are also
officers of the Company. The amount is an advance to the Company to assist with
operations in prior years. This advance is non-interest bearing and has no set
repayment terms.

In accordance with the relevant tax laws and regulations of the PRC, Chaoying
Biotech is entitled to full exemption from Corporation Income Tax ("CIT") for
the first two years and a 50% reduction in CIT for the next three years,
commencing from the first profitable year after offsetting all tax losses
carried forward from the previous five years. As 2003 was Chaoying Biotech's
first profitable year, the Company begins to record 50% CIT provision for first
quarter of 2005. The effective tax rate is approximately 7.5% There is no tax
provision for the quarter ended March 31, 2006, since there is a loss for the
Company's first quarter in 2006.

NOTE D - STOCKHOLDERS' EQUITY

As a result of the reverse merger (see Note A), the common stock of
Cybrdi-Maryland has been cancelled and converted into shares of common stock of
Certron at an exchange ratio of 1.566641609. This resulted in the issuance of
47,328,263 shares of Certron's common stock to the Cybrdi shareholders. As of
March 31, 2006, the Company had 50,456,569 shares of common stock issued and
outstanding. Historical information of the surviving company is that of Cybrdi -
Maryland.

NOTE E - LEGAL PROCEEDINGS

There is no material pending legal proceedings to which the Company is a party.
The Company was notified by a letter dated June 2, 2000 received June 6, 2000
that the Company may have a potential liability from waste disposal in the
Casmalia Disposal Site at Santa Barbara County, California. The Company was
given a choice of either signing an agreement that would toll the statute of
limitations for eighteen (18) months in order to allow the Company to resolve
any liability with the government without incurring costs associated with being
named a defendant in a lawsuit, or becoming an immediate defendant in a lawsuit.
The Company signed the tolling agreement. On November 20, 2001, the tolling
agreement was extended for an additional 18 months. On May 20, 2003 the tolling
agreement was again extended for an additional 18 months and on November 24,
2004 the tolling agreement was again extended for additional 18 months. On June
29, 2004, the Company received a proposed settlement from the EPA in the amount
of $21,131. The Company is waiting for communication from the government
concerning payment of the proposed settlement. As of March 31, 2006, the Company
has accrued a sufficient amount to cover any potential liabilities from this
matter.

Item 2. Management's Discussion and Analysis of Financial Condition and
        Results of Operation

The following discussion and analysis should be read in conjunction with our
Financial Statements and Notes thereto appearing elsewhere in this Report on
Form 10-Q as well as our other SEC filings.

Plan of Operations

With the completion of the merger, management determined to discontinue
Certron's prior business operations, the sale of magnetic media distribution


                                       9
<PAGE>

tapes and products, and pursue business opportunities through Cybrdi, Inc. Most
of Cybrdi's activities are conducted through its 80% equity ownership in China
Shaanxi Shaoying Bio-technology Co., Ltd. ("Chaoying Biotech") a sino-foreign
equity joint venture established in July 2000 in the People's Republic of China.
Cybrdi became affiliated with Chaoying Biotech in March 2003. The Chaoying
Biotech joint venture agreement has a term of 15 years. The term of joint
venture may be extended upon the mutual consent of the parties.

The Company focuses on biogenetics commercialization. The business includes
sales of tissue microarray products and services. Tissue chips, also called
microtissue arrays, represent a newly developed technology providing
high-throughput molecular profiling and parallel analysis of biological and
molecular characteristics for hundreds of pathologically controlled tissue
specimens. Tissue arrays can provide rapid and cost-effective localization and
evaluation of proteins, RNA, or DNA molecules, which is particularly useful for
functioning genomic studies. Cybrdi manufactures both human and animal tissue
microarrays for a wide variety of scientific uses, including drug discovery and
development purposes.

Our principal operations are located in Shaanxi China, where we aim to take
advantage of China's abundant scientific talent, low wage rates, less stringent
biogenetic regulation, and the huge genetic population as it introduces its
growing list of tissue microarray products.

                                       10
<PAGE>

RESULTS OF OPERATIONS

THE FOLLOWING TABLE SETS FORTH CERTAIN ITEMS IN OUR UNAUDITED CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) FOR THE THREE MONTHS ENDED
MARCH 31, 2006 AND MARCH 31, 2005.
<TABLE>
<CAPTION>
                                           FOR THREE MONTHS               FOR THREE MONTHS
                                         ENDED MARCH 31, 2006           ENDED MARCH 31, 2005            2006 VS 2005
                                         --------------------           --------------------         -------------------
                                             (UNAUDITED)                    (UNAUDITED)              INCREASE/(DECREASE)
                                             -----------                    -----------              -------------------
<S>                                           <C>            <C>             <C>            <C>           <C>           <C>
Revenue
      Products                                $  83,218        85%           $ 328,063       92%          $(244,845)      -75%
      Service rendered                           15,121        15%              30,266        8%            (15,145)      -50%
                                              ---------                      ---------                    ---------
           Total revenue                         98,339       100%             358,329      100%           (259,990)      -73%
                                              ---------                      ---------                    ---------
Cost of Sales
      Products                                   43,522                         49,143                       (5,621)      -11%
      Service rendered                               90                          3,476                       (3,386)      -97%
                                              ---------                      ---------                    ---------
           Total cost of sales                   43,612        44%              52,619       15%             (9,007)      -17%
                                              ---------                      ---------                    ---------
Gross Profit                                     54,727        56%             305,710       85%           (250,983)      -82%
                                              ---------                      ---------                    ---------
Operating Expenses:
      Selling and distribution expenses          28,624                         22,531                        6,093        27%
      General and administrative expenses       139,406                        161,717                      (22,311)      -14%
                                              ---------                      ---------                    ---------
Total Operating Expenses                        168,030       171%             184,248       51%            (16,218)       -9%
                                              ---------                      ---------                    ---------
(Loss) Income from Operations                  (113,303)     -115%             121,462       34%           (234,765)     -193%
                                              ---------                      ---------                    ---------
Other Income/(Expenses)
      Interest income                            61,441                          2,058                       59,383      2885%
      Other (expenses)/income, net                2,527                         (3,049)                       5,576      -183%
                                              ---------                      ---------                    ---------
Total Other Income (Expenses)                    63,968        65%                (991)       0%             64,959     -6555%
                                              ---------                      ---------                    ---------
(Loss) Income before Income Taxes               (49,335)                       120,471                     (169,806)     -141%
Income Taxes (Expenses)/Benefit                      --                          8,774                       (8,774)
                                              ---------                      ---------                    ---------
(Loss) Income before Minority Interest          (49,335)      -50%             111,697       31%           (161,032)     -144%
Minority (Loss) Interest                         (2,567)       -3%              21,644        6%            (24,211)     -112%
                                              ---------                      ---------                    ---------
Net (Loss) Income                             $ (46,768)      -48%           $  90,053       25%          $(136,821)     -152%
                                              ---------                      ---------                    ---------
</TABLE>

THREE MONTHS ENDED MARCH 31, 2006 COMPARED TO THREE MONTHS ENDED MARCH 31, 2005

Net Sales

Cybrdi generates two categories of revenues: tissue chip product and services.
The net sales decrease to $98,339 or the three months ended March 31, 2006 from
$358,329 or the three months ended March 31, 2005.

Tissue Chip Product: sales decreased along all product lines in the tissue chip
business. The net sales decreased $244,845 to $83,218 for the three months ended
March 31, 2006 as compared to $328,063 for the three months ended March 31,
2005. The decrease in net sales of our Tissue Chip business is primarily
attributable to the company's new sales policy of restricting the sales to
certain existing customers in China with significantly delinquent past due
amounts. The decrease is partially offset by an increase in international sales.
Sales volume for Tissue Chip Products in China has dropped 3,752 pieces to 83
pieces from 3,835 pieces for the three months ended March 31, 2006 as compared
to March 31, 2005. International sales volume increased by 1,761 pieces to 2,541
pieces from 780 pieces for the three months ended March 31, 2006 as compared to
March 31, 2005. In addition, average selling price is lower for international
customers (RMB111) than for customers in China (RMB577).

Services: Fewer technical service orders were received during the first quarter
of 2006 as compared to 2005 resulting in a decrease in sales of $15,145
declining to $15,121 from $30,266 for the three months ended March 31, 2006 as
compared to March 31, 2005.

                                       11
<PAGE>

Gross Margin

Gross margin as a percent of sales was 56% and 85% for the three months ended
March 31, 2006 and 2005, respectively. Gross profit for the three months ended
March 31, 2006 decreased to $54,727 from $305,710 for the three months ended
March 31, 2005. The primary reason for the decrease is due to decreased sales of
Tissue Chip Products in China, due to the Company new sales policy, which was
partially offset by increased international sales of Tissue Chip Products. The
gross margin decrease was primarily due to the reduction in units of product
sales and thus a higher per unit fixed cost.

Operating Expenses

Our operating expenses decreased to $168,030 for the three months ended March
31, 2006 from $184,248 or the three months ended March 31, 2005. This is
primarily due to a decrease in general and administrative expenses $139,406 for
the three months ended March 31, 2006 from $161,717 for the three months ended
March 31, 2005., and partially offset by an increase in selling and distribution
expenses of $6,093. The decrease in general and administrative expenses was
because Cybrdi incurred higher professional fees and administrative expenses
during its acquisition by Certron in the first quarter of 2005. The increase in
selling expenses is primary due to the membership fee $11,328 (RMB91,183)
allocated from Tinmei Lelier Slim Body Medical Tech in the first quarter of 2006
for the Company to use Lelier's trade mark, technology and products. The
effective period for this membership is from November 10th 2005 to December 31,
2007. For the period from November 10th 2005 (date of membership start) to March
31, 2006, the Company did not generate any income from this membership.

Income Taxes

The Company has not recorded a provision for federal income tax for quarter
ended March 31, 2006 due to utilization of net operating loss carry forward to
offset taxable income in United States. In accordance with the relevant tax laws
and regulations of the People's Republic of China, Chaoying Biotech is entitled
to full exemption from Corporation Income Tax ("CIT") for the first two years
and a 50% reduction in CIT for the next three years, commencing from the first
profitable year after offsetting all tax losses carried forward from the
previous five years. As 2003 was Chaoying Biotech's first profitable year, the
Company begins to record 50% CIT provision from the first quarter of 2005. The
effective income tax rate is 7.5% for the quarter ended March 31, 2006 and 2005.
Due to operating losses for the first t quarter 2006, the Company does not need
to pay income tax for the quarter ended March 31, 2006.

LIQUIDITY AND CAPITAL RESOURCES

Operating working capital (accounts receivable plus inventory less accounts
payable) decreased by $3,859 from $590,019 as of December 31, 2005 to $586,160
as of March 31, 2006. The decrease was primarily due to a decrease in accounts
receivable of $28,250 from $360,503, at December 31, 2005 to $332,253 at March
31, 2006, and an increase in accounts payable of $21,570 from $34,118 at
December 31, 2005 to $55,688 at March 31, 2006, which was offset by an increase
in inventory of $45,961 from $263,634at December 31, 2005 to $309,595 at March
31, 2006. Decrease in net sales on Tissue Chip Product as a result of the
Company's new sales policy is attributable to the decrease in account receivable
and increase in inventory. The increase in accounts payables and accrued
expenses is primary due to unpaid professional fees of $16,355.

Cash consumed from operating activities was $75,152 for the three months ended
March 31, 2006 as compared to $101,336 provided by operating activities for the
three months ended March 31, 2005. The decrease in cash provided by operating
activities reflected net loss and increased in inventory during the quarter
ended March 31, 2006.

The Company has $1,584 and $0 capital expenditure for the three months ended
March 31, 2006 and 2005, respectively. Financing activities for the three months
ended March 31, 2006 consumed $3,670,329 reflecting a repayment of advance from
shareholders of $15,459 and a loan to unaffiliated company of $3,654,870.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Certain statements in this quarterly report on Form 10-QSB contain or may
contain forward-looking statements that are subject to known and unknown risks,
uncertainties and other factors which may cause actual results, performance or
achievements to be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements. These
forward-looking statements were based on various factors and were derived
utilizing numerous assumptions and other factors that could cause our actual


                                       12
<PAGE>

results to differ materially from those in the forward-looking statements. These
factors include, but are not limited to, economic, political and market
conditions and fluctuations, government and industry regulation, interest rate
risk, U.S. and global competition, and other factors. Most of these factors are
difficult to predict accurately and are generally beyond our control. You should
consider the areas of risk described in connection with any forward-looking
statements that may be made herein. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date of
this report. Readers should carefully review this quarterly report in its
entirety, including but not limited to our financial statements and the notes
thereto. Except for our ongoing obligations to disclose material information
under the Federal securities laws, we undertake no obligation to release
publicly any revisions to any forward-looking statements, to report events or to
report the occurrence of unanticipated events. For any forward-looking
statements contained in any document, we claim the protection of the safe harbor
for forward-looking statements contained in the Private Securities Litigation
Reform Act of 1995.

Critical Accounting Policies

Use of Estimates: The preparation of financial statements in conformity with
accounting principles generally accepted in the United States of America
requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and
liabilities at the date of the financial statements and the reported amounts of
revenues and expenses during the reporting period. Actual results could differ
materially from those estimates.

The preparation of financial statements in conformity with generally accepted
accounting principles (GAAP) requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the
reporting period. Actual results may differ from those estimates.

Revenue recognition: Revenue represents the invoiced value of goods sold
recognized upon the delivery of goods to customers and service income is
recognized when services are provided. Deferred revenue represents the
undelivered portion of invoiced value of goods sold to customers. Sales
transactions not meeting all the conditions of the full accrual method are
accounted for using the deposit method of accounting. Under the deposit method,
all costs are capitalized as incurred, and payments received from the buyer are
recorded as customer deposits.

                                       13
<PAGE>

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Foreign Currency Exchange Risk

The majority of our net sales, costs and expenses are priced in Chinese
renminbi. Our assets are predominantly located inside China. Since 1994, the
exchange rate for Renminbi against the United States dollar has remained
relatively stable, with an exchange rate approximately RMB8.28 to US$1.00. On
July 21, 2005, China announced a revaluation of RMB and dropped its peg to the
US dollar. China has moved to a managed float against a basket of currencies.
The exchange rate has been marginally fluctuated since then. However, there can
be no assurance that Renminbi will not be subject to devaluation. We may not be
able to hedge effectively against Renminbi devaluation, so there can be no
assurance that future movements in the exchange rate of Renminbi and other
currencies will not have an adverse effect on our financial condition.

Item 4. Controls and Procedures

An evaluation was carried out by the Company's chief executive officer and
treasurer of the effectiveness of the Company's disclosure controls and
procedures (as defined in Rule 13a-15e or 15(d)-15(e) of the Securities Exchange
Act of 1934) as of March 31, 2006. Based upon that evaluation, the chief
executive officer and the treasurer concluded that the design and operation of
these disclosure controls and procedures were effective after giving affect to
the acquisition of Cybrdi, Inc. by the Company and its obligations to comply
with applicable accounting and disclosure requirements.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

There is no material pending legal proceedings to which the Company is a party.
The Company was notified by a letter dated June 2, 2000 that the Company may
have a potential liability from waste disposal in the Casmalia Disposal Site at
Santa Barbara County, California. The Company was given a choice of either
signing an agreement that would toll the statute of limitations for eighteen
(18) months in order to allow the Company to resolve any liability with the
government without incurring costs associated with being named a defendant in a
lawsuit, or becoming an immediate defendant in a lawsuit. The Company signed the
tolling agreement. On November 20, 2001, the tolling agreement was extended for
an additional 18 months. On May 20, 2003 the tolling agreement was again
extended for an additional 18 months and on November 24, 2004 the tolling
agreement was again extended for additional 18 months. On June 29, 2004, the
Company received a proposed settlement from the EPA in the amount of $21,131.
The Company is waiting for communication from the government concerning payment
of the proposed settlement. As of March 31, 2006, the Company has accrued a
sufficient amount to cover any potential liabilities from this matter.

Item 2. Unregistered Sales of Equity Securities,

None.

Item 3. Defaults upon senior securities.

None.

                                       14
<PAGE>

Item 4. Submission of matters to a vote of security holders.

None.

Item 5. Exhibits and Report on Form 8-K

(a) Exhibits:

    31.1     Rule 13(a)-14(a)/15(d)-14(a) Certification

    31.2     Rule 13(a)-14(a)/15(d)-14(a) Certification

    32.1     Certification Under Section 906 of the Sarbanes-Oxley Act fof 2002

    32.2     Certification Under Section 906 of the Sarbanes-Oxley Act of 2002

(b) Reports on Form 8-K:

    None.

                                       15
<PAGE>
                                    SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned thereunto duly authorized.

                                              CYBRDI, INC.


DATE:  October 16, 2006                       /s/ Yanbiao Bai
                                              -----------------------
                                              Yanbiao Bai
                                              Chief Executive Officer
                                              and president

                                       16